Larin Fe Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Larin Fe 1.5/30 (norethindrone acetate/ethinyl estradiol and ferrous fumarate) is a is a combination of female hormones progestogen and estrogen, with iron supplement tablets used to prevent pregnancy in women who elect to use oral contraceptives as a method of contraception. This medication is available in generic form. Common side effects include nausea, vomiting, abdominal cramps and bloating, spotting, changes in menstrual flow, skin discoloration, breast tenderness, changes in weight, rash, depression, and vaginal yeast infection.
Larin Fe 1.5/30 provides a continuous administration regimen consisting of 21 green tablets of norethindrone acetate and ethinyl estradiol tablets and 7 brown non-hormone containing tablets of ferrous fumarate. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen and do not serve any therapeutic purpose. Larin Fe may interact with rifampin, anticonvulsants, troglitazone, antibiotics, atorvastatin, ascorbic acid, acetaminophen, phenylbutazone, cyclosporine, prednisolone, theophylline, temazepam, salicylic acid, morphine, and clofibric acid. Tell your doctor all medications and supplements you use. Larin Fe is not recommended for use during pregnancy. This drug passes into breast milk and is not recommended for use while breastfeeding.
Our Larin Fe 1.5/30 (norethindrone acetate/ethinyl estradiol and ferrous fumarate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Larin Fe FDA Prescribing Information: Side Effects
An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section):
- Arterial thromboembolism
- Pulmonary embolism
- Myocardial infarction
- Cerebral hemorrhage
- Cerebral thrombosis
- Gallbladder disease
- Hepatic adenomas or benign liver tumors
There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed:
- Mesenteric thrombosis
- Retinal thrombosis
The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:
- Gastrointestinal symptoms (such as abdominal cramps and bloating)
- Breakthrough bleeding
- Change in menstrual flow
- Temporary infertility after discontinuation of treatment
- Melasma which may persist
- Breast changes: tenderness, enlargement, secretion
- Change in weight (increase or decrease)
- Change in cervical erosion and secretion
- Diminution in lactation when given immediately postpartum
- Cholestatic jaundice
- Rash (allergic)
- Mental depression
- Reduced tolerance to carbohydrates
- Vaginal candidiasis
- Change in corneal curvature (steepening)
- Intolerance to contact lenses
The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:
- Pre-menstrual syndrome
- Changes in appetite
- Cystitis-like syndrome
- Loss of scalp hair
- Erythema multiforme
- Erythema nodosum
- Hemorrhagic eruption
- Impaired renal function
- Hemolytic uremic syndrome
- Budd-Chiari syndrome
- Changes in libido
Read the entire FDA prescribing information for Larin Fe (Norethindrone Acetate/Ethinyl Estradiol) Tablets , USP and Ferrous Fumarate Tablets)
Additional Larin Fe Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.